首页> 外文期刊>Journal of affective disorders >Effectiveness of olanzapine monotherapy and olanzapine combination treatment in the long term following acute mania - results of a two year observational study in bipolar disorder (EMBLEM).
【24h】

Effectiveness of olanzapine monotherapy and olanzapine combination treatment in the long term following acute mania - results of a two year observational study in bipolar disorder (EMBLEM).

机译:奥氮平单药治疗和奥氮平联合治疗在急性躁狂后的长期疗效-两年躁郁症(EMBLEM)观察研究的结果。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: This study compared the 2-year outcomes of patients with a manic/mixed episode of bipolar disorder taking olanzapine monotherapy or olanzapine in combination with other agents. METHODS: EMBLEM (European Mania in Bipolar Longitudinal Evaluation of Medication) is a 2-year, prospective, observational study of clinical and functional outcomes of bipolar patients with an index manic/mixed episode. The study consisted of two phases: acute (12 weeks) and maintenance (follow-up over 2 years). The longitudinal outcome measure was the Clinical Global Impression-Bipolar Disorder scale. Cox regression models compared outcomes of both therapy groups using intention-to-treat and switching medication analysis. Treatment-emergent adverse events were also assessed. RESULTS: 1076 patients were included in this analysis. 29% took olanzapine as monotherapy (n = 313) and 71% as combination (n = 763) at 12-weeks post-baseline (end of study acute phase). After adjusting for patient characteristics using switching medication analysis, only relapse rates differed (p = 0.01) in favour of monotherapy-treated patients. There was no significant difference in rates of improvement, remission, and recovery. Patients treated with combination therapy reported more tremor (OR 2.37, 95%CI 1.44-3.89) and polyuria (OR 3.08, 95%CI 1.45-6.54) treatment-emergent events than monotherapy, although weight change was greater in the monotherapy group. LIMITATIONS: Unknown confounding and potential selection bias may differentially impact treatment outcomes. CONCLUSIONS: EMBLEM patients benefitted from the selected therapy to a similar extent. Differences in patient characteristics between those prescribed monotherapy and combination therapy appear to be clinically relevant in the treatment decision. Physicians must balance the benefits and risks when determining appropriate treatment for individual patients.
机译:背景:这项研究比较了躁狂/躁狂躁狂混合发作的躁郁症/躁狂症混合患者接受奥氮平单药治疗或奥氮平联合其他药物的2年结局。方法:EMBLEM(欧洲躁狂症的双向躁郁症药物纵向评估)是一项为期2年的前瞻性观察性研究,对躁郁症/混合性发作的躁郁症患者的临床和功能结局进行了观察。该研究包括两个阶段:急性(12周)和维持(2年随访)。纵向结局指标为临床总体印象-双相情感障碍量表。 Cox回归模型使用意向治疗和转换用药分析比较了两个治疗组的结果。还评估了治疗紧急不良事件。结果:1076例患者被纳入该分析。在基线后12周(研究结束的急性期),有29%的患者接受奥氮平单药治疗(n = 313)和71%的组合药物(n = 763)。使用转换用药分析调整患者特征后,仅复发率有所不同(p = 0.01),有利于接受单药治疗的患者。改善,缓解和恢复率无显着差异。尽管单药治疗组的体重变化更大,但联合治疗的患者发生震颤(OR 2.37,95%CI 1.44-3.89)和多尿(OR 3.08,95%CI 1.45-6.54)的事件比单药多。局限性:未知的混杂因素和潜在的选择偏见可能会不同地影响治疗效果。结论:EMBLEM患者从选择的治疗中受益的程度相似。那些规定的单一疗法和联合疗法之间的患者特征差异似乎在治疗决策中具有临床意义。在为个别患者确定适当的治疗方法时,医生必须权衡利弊。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号